US Patent 7745194 None
Patent 7745194 was granted and assigned to Intralytix on June, 2010 by the United States Patent and Trademark Office.
All edits
Edits on 31 Oct, 2023
Golden AI
Edits made to:
Article (+324 characters)
Article
Patent abstract
The present invention is directed to isolated bacteriophage having strong lytic activity against strains of Staphylococcus aureus, in particular, MRSA, and methods of using that bacteriophage, and/or progeny or derivatives derived therefrom, to control the growth of Staphylococcus aureus in various settings.
Edits on 18 Sep, 2023
Golden AI
Edits made to:
Infobox (+2 properties)
Infobox
Patent Inventor Names
Alexander Sulakvelidze0
Gary R. Pasternack0
Edits on 22 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07745194 None US Patent 7745194 None
Infobox
Patent Number
077451940
Patent Number
77451940
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 25 Mar, 2023
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
077451940
Date of Patent
June 29, 2010
0Patent Application Number
122113470
Date Filed
September 16, 2008
0Official Website
Patent Primary Examiner
Edits on 3 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 4 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07745194 None
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07745194
Date of patent
June 29, 2010
Patent application number
12211347
Date Filed
September 16, 2008
Patent primary examiner
Find more entities like US Patent 7745194 None
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.